Exam Questions Updated On :
250-511 exam Dumps Source : Administration of Symantec(TM) Data Loss(R) Prevention 11
Test Code : 250-511
Test cognomen : Administration of Symantec(TM) Data Loss(R) Prevention 11
Vendor cognomen : Symantec
: 176 existent Questions
Questions own been precisely selfsame as I got!
I passed the 250-511 exam with this package deal from Killexams. I am not inevitable I would own executed it without it! The element is, it covers a massive ambit of subjects, and if you prepare for the exam to your own, with out a confirmed strategy, possibilities are that a few things can descend via the cracks. These are only some regions killexams.com has clearly helped me with there may exist just an extreme amount of information! killexams.com covers the entirety, and given that they disburse actual exam questions passing the 250-511 with much less pressure is lots less difficult.
right location to find 250-511 actual test questions paper.
Hello there fellows, just to disclose you that I passed 250-511 exam a day or two ago with 88% marks. Yes, the exam is arduous and killexams.com and Exam Simulator does invent life simpler - a much deal! I judge this unit is the unrivaled intuition I passed the exam. As a matter of first importance, their exam simulator is a gift. I generally adored the questions and-answer organization and tests of different types in light of the fact that this is the most ideal approach to learn.
it's miles wonderful to own 250-511 actual test questions.
killexams.com material are precisely as excellent, and the percentage spreads complete that it exigency to blanket for an in depth exam planning and that i solved 89/100 questions the usage of them. I were given every simply considered one of them via planning for my tests with killexams.com and exam Simulator, so this one wasnt an exemption. I am capable of assure you that the 250-511 is a ton tougher than past tests, so accumulate prepared to sweat and tension.
Killing the exam promote to exist too easy! I dont import on so.
Passing the 250-511 exam became just impossible for me as I couldnt control my instruction time nicely. Left with handiest 10 days to move, I referred the Exam by using killexams.com and it made my lifestyles clean. Topics were supplied nicely and became dealt well within the test. I scored a terrifi 959. Thanks killexams. I was hopeless but killexams.com given me hope and helped for passing When i was hopeless that i cant emerge as an IT certified; my friend informed me about you; I tried your online Training Tools for my 250-511 exam and became able to accumulate a ninety one bring about Exam. I own pass to killexams.
can you agree with that each one 250-511 questions I had were asked in actual Take a leer at.
that is a gift from killexams.com for complete the applicants to accumulate synchronous test materials for 250-511 exam. complete the individuals of killexams.com are doing a extraordinary activity and ensuring success of candidates in 250-511 exams. I passed the 250-511 exam just because I used killexams.com material.
it is surely excellent revel in to own 250-511 dumps.
the rapid solutions made my instruction more convenient. I completed seventy five questions out off eighty well beneaththe stipulated time and managed 80%. My aspiration to exist a certified Take the exam 250-511. I got the killexams.com manual simply 2 weeks earlier than the exam. thanks.
first rate source latest high-highexcellent 250-511 intellect dumps, redress answers.
killexams.com truly you are maximum top class mentor ever, the manner you train or guide is unmatchable with any other service. I own been given remarkable assist from you in my attempt to try 250-511. I was no longer inevitable approximatelymy fulfillment however you made it in most efficient 2 weeks thats really brilliant. I am very grateful to you for supplying such richhelp that these days i own been able to score super grade in 250-511 exam. If im successful in my discipline its due to you.
surprised to peer 250-511 actual test questions!
I used to exist alluded to the killexams.com dumps as brisk reference for my exam. Genuinely they executed a terrific pastime, i really dote their overall performance and mode of opemarks. The quick-length solutions were a lot less demanding to maintain in brain. I handled ninety eight% questions scoring 80% marks. The exam 250-511 modified birthright into a noteworthy undertaking for my IT profession. On the equal time, I didnt invent a contribution a lot time to set up my-self nicely for this exam.
it's miles excellent best to set aside together 250-511 exam with existent exam questions.
killexams.com is the most nice pass i own ever lengthy beyond over to accumulate geared up and skip IT checks. I desiremore people thought approximately it. But then, there is probably greater risks someone must close it down. The element is, it provides for the selfsame problem what I should apprehend for an exam. Whats more I stand for various IT test, 250-511 with 88% marks. My companion utilized killexams.com for lots special certificates, complete terrific and big. In reality stable, my individual top alternatives.
Do no longer spill ample quantity at 250-511 guides, testout the ones questions.
yes, very beneficial and i was able to marks eighty two% inside the 250-511 exam with five days preparation. especially the facility of downloading as PDF documents on your bundle gave me a terrific play for efficient exercise coupled with online tests - no restricted attempts limit. answers given to every query by using you is one hundred% accurate. thank you plenty.
MOUNTAIN VIEW, Calif.--(business WIRE)--Symantec Corp. (NASDAQ:SYMC), the global leader in cyber safety, today added Symantec advanced haphazard insurance policy (ATP), the first solution that can notice and remediate superior threats across manage facets, from a separate console with only a click, complete and not using a new endpoint agents to set up.
advanced threats, reminiscent of ransomware, far flung entry trojans, advanced persistent threats (APTs) and 0 day attacks, are on the upward thrust and protection authorities can now not depend on the disburse of particular person aspect products at each and every manage element to cease them. The procedure of uncovering risk data across endpoint, community and electronic mail gateways is manual and time-drinking, which offers attackers an side. Symantec ATP correlates suspicious exercise throughout complete manipulate aspects and prioritizes the activities that pose probably the most risk to an organization. once a vital risk is recognized, it will possibly now exist rapidly contained and new instances may too exist blocked.
Symantec ATP makes it feasible for valued clientele to:
“security gurus are constantly on their toes trying to display screen and stop the subsequent cyber-attack,” mentioned Michael A. Brown, president and CEO, Symantec. “We’re relocating the trade forward with Symantec advanced danger protection with the aid of giving clients an entire photo of their gross traffic from a separate console. Now they could lucid out the clamor and quickly find and remediate an assault.”
cutting back the clamor for customers with Symantec ATP occurs in a brace of methods. First, Symantec’s ample world possibility intelligence combined with local customer records means companies own a more redress view of which threats pose the greatest risk interior their infrastructure. moreover, Symantec ATP comprises Symantec CynicTM, a brand new cloud-based sandboxing and payload detonation carrier to find and prioritize nowadays’s most superior threats. It additionally includes SynapseTM, a pass-control aspect correlation faculty that collects suspicious activity across endpoints, networks and e-mail to prioritize people who are of premiere possibility to the firm.
“Our new Synapse and Cynic technologies labor together to supply up to 30 percent superior detection than latest products out there1,” said Balaji Yelamanchili, executive vice president and accepted manager of enterprise security company, Symantec. “earlier than, a security professional would exigency to manually determine to peer if a suspicious file became appropriately blocked. With their new applied sciences constructed into Symantec ATP, they enact the legwork for shoppers, cutting down on their search and remediation time.”
“The regular traffic uses 75 distinctive protection products,” Yelamanchili added. “That overload creates possibility for attackers because it slows down detection. Symantec ATP makes it feasible for security professionals to click on as soon as and remediate complete over across complete three control features.”
Symantec ATP enhances present installations of SymantecTM Endpoint coverage and e mail protection.cloud devoid of requiring any new endpoint brokers. This enables consumers to installation a brand new installing of Symantec ATP in under an hour and hunt attacks in minutes. The product can too export its wealthy intelligence into third birthday celebration security incident undergo managers (SIEMs). As Symantec ATP evolves, the enterprise plans to open it up to third party technology partners, together with firewall and different security product vendors, allowing consumers to enlarge the cost of their current investments.
Pricing and Availability
Symantec superior haphazard coverage might exist obtainable by using conclusion of calendar 12 months 2015.starting MSRP is $40 per person yearly to at ease one manage pointStarting MSRP is $60 per person yearly to cozy two manipulate pointsStarting MSRP is $70 per person annually to relaxed three manage elements
Symantec agency (NASDAQ:SYMC) is the global leader in cybersecurity. operating one of the most world’s largest cyber intelligence networks, they notice more threats, and give protection to greater shoppers from the subsequent era of assaults. We assist organizations, governments and individuals relaxed their most crucial records at any region it lives.
forward-looking STATEMENTS: Any ahead-looking indication of plans for items is prefatory and complete future liberate dates are tentative and are discipline to change. Any future free up of the product or planned modifications to product ability, functionality, or function are discipline to ongoing contrast through Symantec, and might or might too not exist applied and should not exist considered firm commitments by Symantec and may not exist relied upon in making procuring selections.
1 supply: Miercom, Symantec advanced haphazard insurance policy: network, April 2015. http://miercom.com/pdf/experiences/20150218.pdf
Endpoint security products from CrowdStrike and Symantec both made eSecurity Planet's record of top conclusion point detection and response (EDR) solutions – and while each and every product has an abominable lot to tender traffic shoppers, there are key variations between them. What follows an analysis of every solution's key aspects, in addition to some strengths and weaknesses.The basis line
each solutions are rated highly through clients in addition to traffic analysts. CrowdStrike's cloud structure makes deployment strangely short and easy, notwithstanding the incontrovertible fact that or not it's a long pass less beneficial offline makes it unsuitable for air-gapped networks. Symantec offers each an on-premises solution and a cloud-primarily based one, featuring a wider ambit of alternatives for shoppers – but it's frequently considered as being greater complicated to manage than its opponents.CrowdStrike EDR Highlights
Overview: CrowdStrike Falcon insight leverages signatureless AI and indicator-of-assault (IOA) based mostly probability prevention to tender protection to users from complete kinds of cyberattacks. Falcon offers contextualized probability intelligence with particulars on the hazard, and a five-second search tool allows for teams to determine and investigate current and historic possibility exercise by means of going lower back one 2nd, someday or one year of pastime. The solution’s cloud-based mostly architecture is designed to give rapid response without placing any stress on purchasers' endpoints.
recent traits: improvements over the past twelve months encompass:
Analysts' take: Gartner says the combination of Falcon OverWatch with Falcon perception EDR is certainly compelling for businesses with wee or no SOC teams. The Falcon insight EDR agent offers parity throughout home windows, Mac OS and Linux systems, and valued clientele document essential and straightforward deployments, in fraction as a result of the answer's cloud structure. nevertheless, the research firm says Falcon's EDR functionality requires knowledgeable technical personnel to invent disburse of, and its offline insurance plot is vastly superior when related to the cloud-based Falcon platform, making it unsuitable for air-gapped (secure, remoted) networks.Symantec EDR Highlights
Overview: Symantec EDR uses behavioral evaluation at the endpoint and AI-based mostly analytics in the cloud to determine superior assaults. The respond provides a comprehensive set of detection, investigation and remediation capabilities for complete tiers of investigators, together with automatic investigation playbooks and user conduct analytics. Incident responders can immediately search, determine and comprise impacted endpoints whereas investigating threats the usage of a determination of on-premises and cloud-primarily based sandboxing.
recent tendencies: improvements over the ultimate 12 months include:
Analysts' take: Gartner says Symantec is the primary seller to tender malware coverage, EDR, device hardening and deception capabilities in a separate agent, and its great deployment throughout a really tremendous population of both client and company endpoints offers it a very huge view into the haphazard landscape throughout many verticals. still, the research company says Symantec is perceived as extra intricate and useful resource-intensive to manipulate than its competitors, and its managed safety capabilities are extra expensive than those from more recent providers.EDR Product rankings
listed here are eSecurity Planet's scores of every solution's key facets.
performance: shoppers of each vendors record solid performance, with minimal own an sequel on on endpoints. essentially the most fresh Forrester Wave file on EDR options gave CrowdStrike the optimum ranking of complete EDR companies proven – 4.fifty six out of five – and gave Symantec a score of two.72 out of five. The rating is based on a variety of criteria, including configurability, agent effectiveness, forensic capabilities, deployment alternatives and response movements.
Detection and response: In fresh checking out, Forrester rated CrowdStrike's detection capabilities at four.eight out of 5, and its response capabilities at four.6 out of 5. Symantec's detection capabilities were rated at 2.0 out of 5, and its response capabilities at four.2 out of 5. Symantec shoppers report stronger possibility detection and containment with the addition of computer getting to know and other superior anti-malware facets, Gartner noted.
cost: while CrowdStrike is extra expensive than many other options, cloud statistics storage and managed detection and response are protected. Symantec presents managed features, however those features are greater tall priced than those from other providers.
Implementation and management: CrowdStrike's cloud architecture makes deployment certainly effortless, whatever clients time and again cite in studies. Symantec presents each cloud-primarily based and on-premises alternate options, making it more desirable suited for hybrid environments. both options require expert technical personnel to manage, although managed detection and response services can exist found.
assist: Gartner says Symantec purchasers file incongruous assist experiences, even when giant organizations are offered with committed wait on personnel. nevertheless, some reviewers spoke of the identical of CrowdStrike's tech aid.
Cloud features: both organizations present cloud-based mostly options, besides the fact that children CrowdStrike's offering is purely cloud-based, giving Symantec the fraction in hybrid environments.
Gartner Peer Insights clients give CrowdStrike Falcon an medium rating of four.6 out of 5, with Symantec EDR following at a yardstick of four.0 stars out of 5. IT imperative Station clients supply CrowdStrike 4.0 stars out of 5, and Symantec four.1 out of 5.
CrowdStrike reviewers repeatedly stated the product’s ease of deployment, calling it "short and easy to install" and reporting that "the sensor is truly lightweight and has no longer been considerable when operating on even aid-limited computer systems." different reviewers wrote that "the hobbies administration of this respond is manageable," and that CrowdStrike has "a different proposition with their cloud-primarily based manner as neatly because the research group."
Symantec reviewers said that "implementation changed into effortless." They referred to "short whitelisting and blacklisting and informative reporting" as key advantages, including that the respond "has provided visibility insights that they were no longer receiving from other items." yet another reviewer pointed out the product "matches very neatly with their existing strategies and strategies," calling it "a superb product to give protection to your environment."
study more experiences written via users of CrowdStrike and Symantec.Deployment
The CrowdStrike Falcon platform is absolutely cloud-based mostly, allowing it to exist deployed within hours, and supports windows, Mac and Linux programs.
Symantec EDR presents cloud, on-premises and hybrid deployment models, and supports windows, Mac and Linux methods.Pricing
CrowdStrike Falcon insight is purchasable for an annual subscription payment per endpoint, with a free crucible purchasable. AWS gives some pricing information.
Symantec EDR is priced per consumer per 12 months, with quantity discounting. Trials can exist found. CDW presents some pricing information.
A China-based mostly cyber group is carrying out an extensive hacking drive by pass of focused on satellite, telecom and protection organizations in the united states and Southeast Asia, a U.S. cybersecurity company warned this week.
The purpose of the hacking group, called "Thrip," is probably going countrywide cyber espionage, safety researchers at Symantec Corp. mentioned on Tuesday.
"Thrip’s beset on telecoms and satellite tv for pc operators exposes the probability that the attackers could intercept or even alter communications traffic from enterprises and consumers," Symantec spoke of in a press release, including that the most stressful discovery is an try to manipulate satellites by means of infecting linked computer systems with malware.
"The assault community gave the impression to exist principally drawn to the operational aspect of the company, hunting for and infecting computer systems running application that screens and controls satellites. this suggests to us that Thrip’s factors Go beyond spying and can additionally encompass disruption," Symantec wrote in a separate blog publish.
Satellites play a famous function in telecommunications, receiving and transmitting phone and information superhighway alerts as well as mapping and geolocation information.
Symantec observed in Tuesday's observation that it has tracked Thrip in view that 2013 and currently followed that the cyber group looks to own "found out new tools and concepts used via the community in this most fresh set of attacks."
The possibility of the more suitable hacking toolbox is extra compounded by pass of Thrip's means to reside smartly hidden.
"They function very quietly, blending in to networks, and are most efficient establish the disburse of simulated intelligence that may determine and flag their actions," Symantec Chief government Greg Clark renowned in a statement.
The traffic says it establish out the new attacks through its simulated intelligence-based targeted assault Analytics, which helped the researchers spot the malicious habits that become hiding in reputable IT administration equipment.
Obviously it is arduous assignment to pick solid certification questions/answers assets concerning review, reputation and validity since individuals accumulate sham because of picking incorrectly benefit. Killexams.com ensure to serve its customers best to its assets concerning exam dumps update and validity. The vast majority of other's sham report objection customers promote to us for the brain dumps and pass their exams cheerfully and effectively. They never trade off on their review, reputation and quality because killexams review, killexams reputation and killexams customer conviction is vital to us. Uniquely they deal with killexams.com review, killexams.com reputation, killexams.com sham report grievance, killexams.com trust, killexams.com validity, killexams.com report and killexams.com scam. In the event that you notice any erroneous report posted by their rivals with the cognomen killexams sham report grievance web, killexams.com sham report, killexams.com scam, killexams.com dissension or something dote this, simply recollect there are constantly terrible individuals harming reputation of noble administrations because of their advantages. There are a much many fulfilled clients that pass their exams utilizing killexams.com brain dumps, killexams PDF questions, killexams hone questions, killexams exam simulator. Visit Killexams.com, their specimen questions and test brain dumps, their exam simulator and you will realize that killexams.com is the best brain dumps site.
000-M95 test prep | 9A0-058 cram | 700-270 free pdf | SCP-500 free pdf | 8002 braindumps | HP0-335 dumps | 920-451 exercise exam | MB4-213 existent questions | HP0-656 questions answers | 000-348 exercise questions | 4A0-107 test questions | 000-294 free pdf download | 1Z0-863 exercise test | 000-207 bootcamp | COG-622 questions and answers | Firefighter study guide | 920-160 questions and answers | HCE-5710 study guide | C2040-440 examcollection | 70-464 exam questions |
Never miss these 250-511 questions before you Go for test.
killexams.com recommend you to should attempt its free demo, you may notice the characteristic UI and moreover you will assume that its simple to direct the prep mode. Regardless, ensure that, the existent 250-511 protest has a greater scope of questions than the prefatory shape. killexams.com allows you 3 months free updates of 250-511 Administration of Symantec(TM) Data Loss(R) Prevention 11 exam questions. Their confirmation group is consistently reachable at back discontinue who refreshes the material as and when required.
Are you searching out Symantec 250-511 Dumps containing actual test questions and answers for the Administration of Symantec(TM) Data Loss(R) Prevention 11 Exam prep? killexams.com is here to provide you one most updated and fine source of 250-511 Dumps this is http://killexams.com/pass4sure/exam-detail/250-511. They own compiled a database of 250-511 Dumps questions from actual test that allows you to set aside together and pass 250-511 exam on the first attempt.
killexams.com Huge Discount Coupons and Promo Codes are as underneath;
WC2017 : 60% Discount Coupon for complete tests on website
PROF17 : 10% Discount Coupon for Orders greater than $69
DEAL17 : 15% Discount Coupon for Orders more than $ninety nine
DECSPECIAL : 10% Special Discount Coupon for complete Orders
The top notch approach to accumulate accomplishment inside the Symantec 250-511 exam is that you own to amass dependable braindumps. They guarantee that killexams.com is the greatest direct pathway toward confirming Symantec Administration of Symantec(TM) Data Loss(R) Prevention 11 exam. You might exist confident with replete fact. You can notice free inquiries at killexams.com sooner than you purchase the 250-511 exam contraptions. Their brain dumps are in various determination the selfsame As the genuine exam design. The inquiries and answers made by the guaranteed experts. They judge of the delight in of stepping through the existent exam. 100% assurance to pass the 250-511 existent check.
killexams.com Symantec Certification mull over distributions are setup by utilizing IT authorities. Clusters of understudies own been crying that too much several inquiries in such colossal quantities of tutoring tests and study assistants, and they're of late exhausted to control the imbue of any additional. Seeing killexams.com pros exercise session this gigantic shape while quiet accreditation that complete the data is anchored after significant examinations and exam. Everything is to invent encouragement for rivalry on their road to certification.
We own Tested and Approved 250-511 Exams. killexams.com offers the redress and latest IT exam materials which basically involve complete data centers. With the guide of their 250-511 brain dumps, you don't ought to squander your plausibility on examining existent piece of reference books and for complete intents and purposes exigency to consume 10-20 hours to pro their 250-511 existent issues and replies. Additionally, they supply you with PDF Version and Software Version exam inquiries and answers. For Software Version materials, Its displayed to give indistinguishable undergo from the Symantec 250-511 exam in a genuine environment.
We supply free updates. Inside authenticity length, if 250-511 brain dumps that you own purchased updated, they will insinuate you by electronic mail to down load most current model of . if you don't pass your Symantec Administration of Symantec(TM) Data Loss(R) Prevention 11 exam, They will give you finish discount. You exigency to dispatch the verified propagation of your 250-511 exam archive card to us. Ensuing to keeping up, they can quickly judge of replete REFUND.
In the occasion which you prepare for the Symantec 250-511 exam utilizing their testing programming program. It is whatever anyway violent to exist triumphant for complete certifications inside the most imperative endeavor. You don't exigency to deal with complete dumps or any free deluge/rapidshare complete stuff. They give free demo of every IT Certification Dumps. You can examine the interface, probe superb and solace of their instruction appraisals sooner than you purchase.
killexams.com Huge Discount Coupons and Promo Codes are as under;
WC2017: 60% Discount Coupon for complete exams on website
PROF17: 10% Discount Coupon for Orders greater than $69
DEAL17: 15% Discount Coupon for Orders greater than $99
DECSPECIAL: 10% Special Discount Coupon for complete Orders
250-511 Practice Test | 250-511 examcollection | 250-511 VCE | 250-511 study guide | 250-511 practice exam | 250-511 cram
Killexams 000-753 bootcamp | Killexams HPE6-A43 brain dumps | Killexams 050-688 braindumps | Killexams 3X0-201 study guide | Killexams JK0-023 braindumps | Killexams 000-018 study guide | Killexams M2080-713 questions and answers | Killexams 1Y0-371 exercise test | Killexams LOT-981 free pdf download | Killexams 000-593 existent questions | Killexams 132-S-911-3 study guide | Killexams 000-014 exercise Test | Killexams HP0-M49 test questions | Killexams 3104 dumps | Killexams C2090-623 exam prep | Killexams MCAT mock exam | Killexams 9L0-622 free pdf | Killexams HP0-S26 cram | Killexams AP0-001 dump | Killexams A2010-573 questions and answers |
Killexams 920-115 bootcamp | Killexams 1Z0-595 examcollection | Killexams 920-165 free pdf download | Killexams VCS-412 study guide | Killexams 000-426 exercise exam | Killexams 00M-624 exercise test | Killexams 310-814 mock exam | Killexams 650-148 sample test | Killexams DMV test prep | Killexams HP0-M18 exercise test | Killexams 000-970 dump | Killexams 050-683 braindumps | Killexams I10-001 test prep | Killexams 000-228 study guide | Killexams 00M-230 braindumps | Killexams NSE8 existent questions | Killexams 500-051 exam prep | Killexams 000-301 cheat sheets | Killexams C2050-241 existent questions | Killexams 650-367 test prep |
—APeX-2 24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019—
—Full ZENITH-1 results authenticate safety and efficacy profile of oral 750 mg BCX7353 for upcoming aspect 3 crucible in acute treatment of HAE—
—Oral Factor D inhibitor, BCX9930, advancing to aspect 1 evolution for complement-mediated diseases—
—Recent $100 million debt financing increases monetary flexibility—
RESEARCH TRIANGLE PARK, N.C., March 04, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (BCRX) today announced monetary results for the fourth quarter and replete year ended December 31, 2018, and provided a corporate update.
“In a year with many transformative milestones for BioCryst, it has been exciting to notice so much progress already in the first two months of the year. The stout aspect 2 clinical data from their now-completed ZENITH-1 crucible propels their BCX7353 acute program for HAE into aspect 3 development. With the very conducive preclinical profile of BCX9930, another novel BioCryst-invented oral drug for rare diseases, they are advancing that program into the clinic in the second quarter for the treatment of complement-mediated diseases. They too added further rare disease expertise to their board and increased their monetary flexibility with a $100 million debt agreement,” said Jon Stonehouse, president and chief executive officer of BioCryst.
“We remain on-track for the readout of their APeX-2 crucible next quarter, and an NDA filing of BCX7353 for HAE prophylaxis by the discontinue of the year. They are thoughtfully building their commercial leadership and infrastructure to execute a successful launch that meets the pressing claim for a once-daily oral therapy that will allow HAE patients to live a more timehonored life,” Stonehouse added.
Fourth Quarter 2018 Corporate Developments
Upcoming Key Milestones
HAE Program – BCX7353
Complement Factor D Inhibitor Program – BCX9930
ALK-2 Inhibitor Program – BCX9250
Fourth Quarter 2018 monetary Results
For the three months ended December 31, 2018, total revenues were $2.7 million, compared to $3.9 million in the fourth quarter of 2017. The dwindle was primarily due to a reduction of royalty revenue associated with differences in the onset and severity of the influenza seasons between the two periods. This dwindle was partially offset by increased revenue from government contracts for galidesivir development, which was higher in the fourth quarter of 2018.
Research and evolution (R&D) expenses for the fourth quarter of 2018 increased to $23.4 million from $16.9 million in the fourth quarter of 2017, primarily due to increased spending on the company’s HAE and preclinical programs.
General and administrative (G&A) expenses for the fourth quarter of 2018 decreased slightly to $4.5 million, compared to $4.7 million in the fourth quarter of 2017. The dwindle was primarily due to the want of merger-related costs in the fourth quarter of 2018 associated with the company’s terminated merger with Idera Pharmaceuticals, Inc. (Idera). The dwindle in G&A expense due to the want of merger expenses was largely offset by higher commercial and medical affairs expenses in the fourth quarter of 2018.
Interest expense was $2.4 million in the fourth quarter of 2018, compared to $2.2 million in the fourth quarter of 2017 and was associated with enhancing their secured credit facility in July 2018.
Net loss for the fourth quarter of 2018 was $27.4 million, or $0.25 per share, compared to a net loss of $19.5 million, or $0.20 per share, for the fourth quarter of 2017.
Cash, cash equivalents and investments totaled $128.4 million at December 31, 2018, and reflect a dwindle from $159.0 million at December 31, 2017. Cash and investments reflect the proceeds from a July 2018 enhancement to their secured credit facility and an August 2018 public equity offering, offset by timehonored operating expenses and merger-related costs incurred in the 12-month period. Operating cash disburse for the fourth quarter of 2018 was $22.6 million, and for the replete year of 2018 was $93.4 million.
On February 6, 2019, the company announced it had entered into a $100 million secured credit facility with MidCap monetary faith which further enhanced the company’s cash position with $20 million of immediate additional non-dilutive capital and provided additional monetary flexibility by providing the faculty to draw another $50 million of milestone-based non-dilutive capital.
Full Year 2018 monetary Results
For the replete year ended December 31, 2018, total revenues were $20.7 million, compared to $25.2 million in the replete year ended December 31, 2017. The dwindle in revenue was primarily associated with infrequent revenue events that occurred in 2017 that did not recur in 2018, as well as a $2.1 million dwindle in revenue associated with evolution activities under U.S. government contracts in 2018. The non-recurring 2017 events were the recognition of $4.1 million of royalty revenue from Japanese government stockpiling of RAPIACTA® and the recognition of $1.5 million of peramivir product sales from the company’s commercial partner, Green Cross Corporation. These decreases were partially offset by a $5.0 million milestone associated with the European Medicines Agency’s (EMA) approval of peramivir (ALPIVABTM) recognized in the second quarter of 2018.
R&D expenses in 2018 increased to $84.9 million from $67.0 million in 2017, primarily due to increased spending on their HAE and preclinical programs. These increases were partially offset by a dwindle in the company’s peramivir and galidesivir evolution spending in 2018.
G&A expenses in 2018 increased to $29.5 million, compared to $13.9 million in 2017. The enlarge was primarily due to approximately $11 million of merger-related costs associated with the company’s terminated merger with Idera and a $4.9 million reserve for collectability of the EMA approval milestone of peramivir.
Interest expense was $9.2 million in 2018, compared to $8.6 million in 2017.
Net loss for 2018 was $101.3 million, or $0.98 per share, compared to a net loss of $65.8 million, or $0.78 per share, for 2017.
Financial Outlook for 2019
BioCryst expects net operating cash disburse to exist in the ambit of $105 to $130 million, and its 2019 operating expenses to exist in the ambit of $120 to $145 million. The company’s operating expense ambit excludes equity-based compensation expense due to the vicissitude in reliably projecting this expense, as it is impacted by the volatility and expense of the company’s stock, as well as by the vesting of the company’s outstanding performance-based stock options.
Conference convoke and Webcast
BioCryst management will host a conference convoke and webcast at 8:30 a.m. ET today to argue the monetary results and provide a corporate update. The live convoke may exist accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 1271286. A live webcast of the convoke and any slides will exist available online at the investors section of the company website at www.biocryst.com. A telephone replay of the convoke will exist available by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference ID# 1271286.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. BioCryst has several ongoing evolution programs including BCX7353, an oral treatment for hereditary angioedema, BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, galidesivir, a potential treatment for Marburg virus disease and Yellow Fever, and a preclinical program to develop oral ALK-2 inhibitors for the treatment of fibrodysplasia ossificans progressiva. RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan, Korea and the European Union. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company's website at www.BioCryst.com.
This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause BioCryst’s actual results, performance or achievements to exist materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect their current views with respect to future events and are based on assumptions and are matter to risks and uncertainties. Given these uncertainties, you should not region undue reliance on these forward-looking statements. Some of the factors that could strike the forward-looking statements contained herein include: that developing any HAE product candidate may Take longer or may exist more expensive than planned; that ongoing and future preclinical and clinical evolution of BCX9930, BCX9250 and their HAE second generation drug candidates (including APeX-2, APeX-S and APeX-J) may not own positive results; that BioCryst may not exist able to enroll the required number of subjects in planned clinical trials of product candidates; that the company may not promote human clinical trials with product candidates as expected; that the FDA, EMA or other applicable regulatory agency may require additional studies beyond the studies planned for product candidates, or may not provide regulatory clearances which may result in retard of planned clinical trials, or may impose a clinical hold with respect to such product candidate, or withhold market approval for product candidates; that actual monetary results may not exist consistent with expectations, including that 2019 operating expenses and cash usage may not exist within management's expected ranges. please refer to the documents BioCryst files periodically with the Securities and Exchange Commission, specifically BioCryst’s most recent Annual Report on profile 10-K, Quarterly Reports on profile 10-Q, and Current Reports on profile 8-K, complete of which identify famous factors that could cause the actual results to disagree materially from those contained in BioCryst’s projections and forward-looking statements.
Contact:John Bluth+1 919 859 firstname.lastname@example.orgBIOCRYST PHARMACEUTICALS, INC. CONSOLIDATED monetary SUMMARY (in thousands, except per share) Statements of Operations (Unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2018 2017 2018 2017 Revenues: Product sales $ - $ - $ - $ 1,501 Royalty revenue 1,775 3,291 6,101 10,543 Collaborative and other research and development 954 599 14,552 13,142 Total revenues 2,729 3,890 20,653 25,186 Expenses: Cost of product sales - - - 1,142 Research and development 23,431 16,924 84,888 66,962 General and administrative 4,490 4,698 29,514 13,933 Royalty 70 129 471 560 Total operating expenses 27,991 21,751 114,873 82,597 Loss from operations (25,262 ) (17,861 ) (94,220 ) (57,411 ) Interest and other income 686 478 2,252 1,015 Interest expense (2,414 ) (2,231 ) (9,176 ) (8,565 ) (Loss) gain on curious currency derivative (442 ) 71 (108 ) (821 ) Net loss $ (27,432 ) $ (19,543 ) $ (101,252 ) $ (65,782 ) Basic and diluted net loss per common share $ (0.25 ) $ (0.20 ) $ (0.98 ) $ (0.78 ) Weighted medium shares outstanding 109,802 98,402 103,185 84,451 Balance Sheet Data (in thousands) December 31, 2018 December 31, 2017 (Unaudited) (Note 1) Cash, cash equivalents and investments $ 126,843 $ 155,692 Restricted cash 1,544 3,286 Receivables from collaborations 4,293 6,117 Total assets 146,841 178,259 Non-recourse notes payable 29,121 28,682 Senior credit facility 29,952 23,214 Accumulated deficit (731,969 ) (631,843 ) Stockholders’ equity 49,235 83,767 Shares of common stock outstanding 110,063 98,411 Note 1: Derived from audited monetary statements.
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23–34.
Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD. Immune modulation in cancer with antibodies. Annu Rev Med. 2014;65:185–202.
Ott PA, Elez E, Hiret S, Kim DW, Morosky A, Saraf S, et al. Pembrolizumab in patients with extensive-stage wee cell lung cancer: updated survival results from KEYNOTE-028 2016. J Clin Oncol. 2017;35:3823–9.
Taylor M, Antonia S, Bendell J, Calvo E, Jäger D, de Braud F, et al. aspect I/II study of nivolumab with or without ipilimumab for treatment of recurrent wee cell lung cancer (SCLC): CA209-032. J Immunotherapy Cancer. 2015;3:P376.
Antonia SJ, Lopez-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab lonesome and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, aspect 1/2 trial. Lancet Oncol. 2016;17:883–95.
Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.
Chen HL, Gabrilovich D, Tampe R, Girgis KR, Nadaf S, Carbone DP. A functionally defective allele of TAP1 results in loss of MHC class I antigen presentation in a human lung cancer. Nat Genet. 1996;13:210–3.
Zaretsky JM, Garcia-Diaz A, Shin DS, Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819–29.
Yoshihama S, Roszik J, Downs I, Meissner TB, Vijayan S, Chapuy B, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci USA. 2016;113:5999–6004.
Dalmau J, Graus F, Cheung NK, Rosenblum MK, Ho A, Canete A, et al. Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and wee cell lung cancer. Cancer. 1995;75:99–109.
Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood. 2010;116:1035–44.
Shah MH, Lorigan P, O’Brien ME, Fossella FV, Moore KN, Bhatia S, et al. aspect I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors. Invest New Drugs. 2016;34:290–9.
Feng Y, Wang Y, Zhu Z, Li W, Sussman RT, Randall M, et al. Differential killing of CD56-expressing cells by drug-conjugated human antibodies targeting membrane-distal and membrane-proximal non-overlapping epitopes. MAbs. 2016;8:799–810.
Graus F, Dalmou J, Rene R, Tora M, Malats N, Verschuuren JJ, et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol. 1997;15:2866–72.
Kazarian M, Laird-Offringa IA. Small-cell lung cancer-associated autoantibodies: potential applications to cancer diagnosis, early detection, and therapy. Mol Cancer. 2011;10:33.
Winter SF, Sekido Y, Minna JD, McIntire D, Johnson BE, Gazdar AF, et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. J Natl Cancer Inst. 1993;85:2012–8.
Schreiber RD, feeble LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331:1565–70.
Noble A, Giorgini A, Leggat JA. Cytokine-induced IL-10-secreting CD8 T cells limn a phenotypically discrete suppressor T-cell lineage. Blood. 2006;107:4475–83.
Kelly-Rogers J, Madrigal-Estebas L, O’Connor T, Doherty DG. Activation-induced expression of CD56 by T cells is associated with a reprogramming of cytolytic activity and cytokine secretion profile in vitro. Hum Immunol 2006;67:863–73.
Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, et al. Systematic characterization of human CD8 + T cells with natural killer cell markers in comparison with natural killer cells and timehonored CD8 + T cells. Immunology. 2001;103:281–90.
Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8 + T cells closely correlates with CD56 surface expression. J Immunol. 2000;164:1148–52.
Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, et al. aspect 1/2 study of the CD56-targeting antibody-drug conjugate lorvotuzumab mertansine (IMGN901) in combination with carboplatin/etoposide in small-cell lung cancer patients with extensive-stage disease. Clin Lung Cancer. 2017;18:68–76. e62
Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, et al. Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against wee cell lung cancer in human xenograft models. MAbs. 2014;6:556–66.
Doyle A, Martin WJ, Funa K, Gazdar A, Carney D, Martin SE, et al. Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer. J Exp Med. 1985;161:1135–51.
Fisk B, Ioannides CG, Aggarwal S, Wharton JT, O’Brian CA, Restifo N, et al. Enhanced expression of HLA-A,B,C and inducibility of TAP-1, TAP-2, and HLA-A,B,C by interferon-gamma in a multidrug-resistant wee cell lung cancer line. Lymphokine Cytokine Res. 1994;13:125–31.
Yazawa T, Ito T, Kamma H, Suzuki T, Okudela K, Hayashi H, et al. Complicated mechanisms of class II transactivator transcription deficiency in wee cell lung cancer and neuroblastoma. Am J Pathol. 2002;161:291–300.
Ryan SO, Turner MS, Gariepy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially strike cancer vaccine responses. Cancer Res. 2010;70:5788–96.
Bruns M, Wanger J, Schumacher U, Deppert W. T-cell epitope energy in WAP-T mouse mammary carcinomas is an famous determinant in PD1/PD-L1 immune checkpoint blockade therapy. Oncotarget. 2016;7:64543–59.
Michielsen AJ, Noonan S, Martin P, Tosetto M, Marry J, Biniecka M, et al. Inhibition of dendritic cell maturation by the tumor microenvironment correlates with the survival of colorectal cancer patients following bevacizumab treatment. Mol Cancer Ther. 2012;11:1829–37.
Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, et al. A Tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4:658–68.
Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, et al. Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Ther. 2016;23:615–26.
Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5:215ra172.
Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized. Cell Sens Response Behav Using Synth Notch Recept Cell. 2016;164:780–91.
Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961–71.
Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S, Switzer K, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516–27.
Dr. Bristow - Photo
Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc.
ARCA biopharma, Inc.
WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported monetary results for the quarter ended June 30, 2018.
“The second quarter of this year saw an famous milestone for the Gencaro evolution program with the completion of an End-of-Phase 2 FDA meeting that provided famous guidance for the next steps in their evolution of Gencaro as potentially the first genetically-targeted treatment for atrial fibrillation,” commented Dr. Michael Bristow, ARCA’s President and Chief Executive Officer. “With labor underway on completing the Gencaro aspect 3 crucible protocol and continued progress with IND enabling activities for AB171 in PAD and HF, they believe ARCA is advancing their pipeline of genetically-targeted therapeutics to address the unmet medical needs of patients with cardiovascular disease.”
Gencaro (bucindolol hydrochloride) - a pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation (AF) and inveterate heart failure with reduced left ventricular ejection fraction (HFrEF).
AB171 – a thiol-substituted isosorbide mononitrate being developed as a potential genetically-targeted treatment for heart failure (HF) and peripheral arterial disease (PAD).
Second Quarter 2018 Summary monetary Results
Cash, cash equivalents and marketable securities totaled $9.6 million as of June 30, 2018, compared to $11.8 million as of December 31, 2017. ARCA believes that its current cash, cash equivalents and marketable securities will exist sufficient to fund its operations, at its projected cost structure, through the discontinue of the first quarter of 2019.
Research and evolution (R&D) expenses for the quarter ended June 30, 2018 totaled $1.2 million compared to $4.5 million for the corresponding term of 2017. The $3.3 million dwindle in research and evolution expenses in the second quarter of 2018 as compared to the second quarter 2017 was primarily due to decreased clinical expenses following the completion of the GENETIC-AF clinical trial. The Company expects R&D expenses in 2018 to exist lower than 2017 as the GENETIC-AF clinical crucible has been completed.
General and administrative (G&A) expenses for the quarter ended June 30, 2018 were $1.0 million, relatively unchanged compared to the $1.1 million in the second quarter of 2017. ARCA expects G&A expenses in 2018 to exist consistent with those in 2017 as it maintains administrative activities to champion ongoing operations.
Total operating expenses for the quarter ended June 30, 2018 were $2.2 million compared to $5.6 million for the second quarter of 2017. The dwindle in total operating expenses for the second quarter of 2018 was primarily due to the dwindle in R&D expense due to the completion of the GENETIC-AF clinical trial.
Net loss was $2.1 million, or $0.15 per share, for the second quarter of 2018 compared to $5.5 million, or $0.59 per share, for the second quarter of 2017.
About ARCA biopharma
ARCA biopharma is dedicated to developing genetically-targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. ARCA’s lead product candidate, GencaroTM (bucindolol hydrochloride), is an investigational, pharmacologically unique beta-blocker and mild vasodilator being developed for the potential treatment of patients with atrial fibrillation (AF) and inveterate heart failure with reduced left ventricular ejection fraction (HFrEF) which recently completed a aspect 2B clinical trial. ARCA has identified common genetic variations that it believes prognosticate individual patient response to Gencaro, giving it the potential to exist the first genetically-targeted AF prevention treatment. ARCA has a collaboration with Medtronic, Inc. for champion of the GENETIC-AF trial. The Gencaro evolution program has been granted rapid Track designation by FDA. ARCA is too developing AB171, a thiol-substituted isosorbide mononitrate, as a potential genetically-targeted treatment for peripheral arterial disease (PAD) and for heart failure (HF). For more information, please visit www.arcabio.com.
Safe Harbor Statement
This press release contains "forward-looking statements" for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the faculty of ARCA’s monetary resources to champion its operations through the discontinue of the first quarter of 2019, potential future evolution plans for Gencaro, the expected features and characteristics of Gencaro or AB171, including the potential for genetic variations to prognosticate individual patient response to Gencaro, Gencaro’s potential to treat AF, AB171’s potential to treat HF, future treatment options for patients with AF, and the potential for Gencaro to exist the first genetically-targeted AF prevention treatment. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could disagree materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the risks and uncertainties associated with: ARCA’s monetary resources and whether they will exist sufficient to meet its traffic objectives and operational requirements; ARCA may not exist able to raise sufficient capital on acceptable terms, or at all, to continue evolution of Gencaro or to otherwise continue operations in the future; results of earlier clinical trials may not exist confirmed in future trials; the protection and market exclusivity provided by ARCA’s intellectual property; risks related to the drug discovery and the regulatory approval process; and, the impact of competitive products and technological changes. These and other factors are identified and described in more detail in ARCA’s filings with the Securities and Exchange Commission, including without limitation ARCA’s annual report on profile 10-K for the year ended December 31, 2017, and subsequent filings. ARCA disclaims any intent or duty to update these forward-looking statements.
Investor & Media Contact:Derek Cole720.email@example.com
(Tables follow)ARCA BIOPHARMA, INC. BALANCE SHEET DATA (in thousands) (unaudited) June 30, 2018 December 31, 2017 Cash, cash equivalents & marketable securities $9,635 $11,752 Working capital $8,950 $10,229 Total assets $10,067 $12,365 Total stockholders’ equity $8,998 $10,275
ARCA BIOPHARMA, INC. STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 (in thousands, except participate and per participate amounts) Costs and expenses: Research and development $ 1,154 $ 4,508 $ 2,874 $ 7,754 General and administrative 1,002 1,051 2,055 2,186 Total costs and expenses 2,156 5,559 4,929 9,940 Loss from operations (2,156 ) (5,559 ) (4,929 ) (9,940 ) Interest and other income 43 39 84 84 Interest expense (3 ) (2 ) (6 ) (4 ) Net loss $ (2,116 ) $ (5,522 ) $ (4,851 ) $ (9,860 ) Change in unrealized loss on marketable securities — 4 2 14 Comprehensive loss $ (2,116 ) $ (5,518 ) $ (4,849 ) $ (9,846 ) Net loss per share: Basic and diluted $ (0.15 ) $ (0.59 ) $ (0.35 ) $ (1.07 ) Weighted medium shares outstanding: Basic and diluted 13,923,512 9,324,822 13,772,947 9,210,186
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/af496e97-20da-420a-bf93-e51b3a3ed740
3COM [8 Certification Exam(s) ]
AccessData [1 Certification Exam(s) ]
ACFE [1 Certification Exam(s) ]
ACI [3 Certification Exam(s) ]
Acme-Packet [1 Certification Exam(s) ]
ACSM [4 Certification Exam(s) ]
ACT [1 Certification Exam(s) ]
Admission-Tests [13 Certification Exam(s) ]
ADOBE [93 Certification Exam(s) ]
AFP [1 Certification Exam(s) ]
AICPA [2 Certification Exam(s) ]
AIIM [1 Certification Exam(s) ]
Alcatel-Lucent [13 Certification Exam(s) ]
Alfresco [1 Certification Exam(s) ]
Altiris [3 Certification Exam(s) ]
Amazon [2 Certification Exam(s) ]
American-College [2 Certification Exam(s) ]
Android [4 Certification Exam(s) ]
APA [1 Certification Exam(s) ]
APC [2 Certification Exam(s) ]
APICS [2 Certification Exam(s) ]
Apple [69 Certification Exam(s) ]
AppSense [1 Certification Exam(s) ]
APTUSC [1 Certification Exam(s) ]
Arizona-Education [1 Certification Exam(s) ]
ARM [1 Certification Exam(s) ]
Aruba [8 Certification Exam(s) ]
ASIS [2 Certification Exam(s) ]
ASQ [3 Certification Exam(s) ]
ASTQB [8 Certification Exam(s) ]
Autodesk [2 Certification Exam(s) ]
Avaya [101 Certification Exam(s) ]
AXELOS [1 Certification Exam(s) ]
Axis [1 Certification Exam(s) ]
Banking [1 Certification Exam(s) ]
BEA [5 Certification Exam(s) ]
BICSI [2 Certification Exam(s) ]
BlackBerry [17 Certification Exam(s) ]
BlueCoat [2 Certification Exam(s) ]
Brocade [4 Certification Exam(s) ]
Business-Objects [11 Certification Exam(s) ]
Business-Tests [4 Certification Exam(s) ]
CA-Technologies [20 Certification Exam(s) ]
Certification-Board [10 Certification Exam(s) ]
Certiport [3 Certification Exam(s) ]
CheckPoint [43 Certification Exam(s) ]
CIDQ [1 Certification Exam(s) ]
CIPS [4 Certification Exam(s) ]
Cisco [318 Certification Exam(s) ]
Citrix [48 Certification Exam(s) ]
CIW [18 Certification Exam(s) ]
Cloudera [10 Certification Exam(s) ]
Cognos [19 Certification Exam(s) ]
College-Board [2 Certification Exam(s) ]
CompTIA [76 Certification Exam(s) ]
ComputerAssociates [6 Certification Exam(s) ]
Consultant [2 Certification Exam(s) ]
Counselor [4 Certification Exam(s) ]
CPP-Institute [4 Certification Exam(s) ]
CSP [1 Certification Exam(s) ]
CWNA [1 Certification Exam(s) ]
CWNP [13 Certification Exam(s) ]
CyberArk [1 Certification Exam(s) ]
Dassault [2 Certification Exam(s) ]
DELL [11 Certification Exam(s) ]
DMI [1 Certification Exam(s) ]
DRI [1 Certification Exam(s) ]
ECCouncil [22 Certification Exam(s) ]
ECDL [1 Certification Exam(s) ]
EMC [128 Certification Exam(s) ]
Enterasys [13 Certification Exam(s) ]
Ericsson [5 Certification Exam(s) ]
ESPA [1 Certification Exam(s) ]
Esri [2 Certification Exam(s) ]
ExamExpress [15 Certification Exam(s) ]
Exin [40 Certification Exam(s) ]
ExtremeNetworks [3 Certification Exam(s) ]
F5-Networks [20 Certification Exam(s) ]
FCTC [2 Certification Exam(s) ]
Filemaker [9 Certification Exam(s) ]
Financial [36 Certification Exam(s) ]
Food [4 Certification Exam(s) ]
Fortinet [14 Certification Exam(s) ]
Foundry [6 Certification Exam(s) ]
FSMTB [1 Certification Exam(s) ]
Fujitsu [2 Certification Exam(s) ]
GAQM [9 Certification Exam(s) ]
Genesys [4 Certification Exam(s) ]
GIAC [15 Certification Exam(s) ]
Google [4 Certification Exam(s) ]
GuidanceSoftware [2 Certification Exam(s) ]
H3C [1 Certification Exam(s) ]
HDI [9 Certification Exam(s) ]
Healthcare [3 Certification Exam(s) ]
HIPAA [2 Certification Exam(s) ]
Hitachi [30 Certification Exam(s) ]
Hortonworks [4 Certification Exam(s) ]
Hospitality [2 Certification Exam(s) ]
HP [752 Certification Exam(s) ]
HR [4 Certification Exam(s) ]
HRCI [1 Certification Exam(s) ]
Huawei [21 Certification Exam(s) ]
Hyperion [10 Certification Exam(s) ]
IAAP [1 Certification Exam(s) ]
IAHCSMM [1 Certification Exam(s) ]
IBM [1533 Certification Exam(s) ]
IBQH [1 Certification Exam(s) ]
ICAI [1 Certification Exam(s) ]
ICDL [6 Certification Exam(s) ]
IEEE [1 Certification Exam(s) ]
IELTS [1 Certification Exam(s) ]
IFPUG [1 Certification Exam(s) ]
IIA [3 Certification Exam(s) ]
IIBA [2 Certification Exam(s) ]
IISFA [1 Certification Exam(s) ]
Intel [2 Certification Exam(s) ]
IQN [1 Certification Exam(s) ]
IRS [1 Certification Exam(s) ]
ISA [1 Certification Exam(s) ]
ISACA [4 Certification Exam(s) ]
ISC2 [6 Certification Exam(s) ]
ISEB [24 Certification Exam(s) ]
Isilon [4 Certification Exam(s) ]
ISM [6 Certification Exam(s) ]
iSQI [7 Certification Exam(s) ]
ITEC [1 Certification Exam(s) ]
Juniper [65 Certification Exam(s) ]
LEED [1 Certification Exam(s) ]
Legato [5 Certification Exam(s) ]
Liferay [1 Certification Exam(s) ]
Logical-Operations [1 Certification Exam(s) ]
Lotus [66 Certification Exam(s) ]
LPI [24 Certification Exam(s) ]
LSI [3 Certification Exam(s) ]
Magento [3 Certification Exam(s) ]
Maintenance [2 Certification Exam(s) ]
McAfee [8 Certification Exam(s) ]
McData [3 Certification Exam(s) ]
Medical [68 Certification Exam(s) ]
Microsoft [375 Certification Exam(s) ]
Mile2 [3 Certification Exam(s) ]
Military [1 Certification Exam(s) ]
Misc [1 Certification Exam(s) ]
Motorola [7 Certification Exam(s) ]
mySQL [4 Certification Exam(s) ]
NBSTSA [1 Certification Exam(s) ]
NCEES [2 Certification Exam(s) ]
NCIDQ [1 Certification Exam(s) ]
NCLEX [3 Certification Exam(s) ]
Network-General [12 Certification Exam(s) ]
NetworkAppliance [39 Certification Exam(s) ]
NI [1 Certification Exam(s) ]
NIELIT [1 Certification Exam(s) ]
Nokia [6 Certification Exam(s) ]
Nortel [130 Certification Exam(s) ]
Novell [37 Certification Exam(s) ]
OMG [10 Certification Exam(s) ]
Oracle [282 Certification Exam(s) ]
P&C [2 Certification Exam(s) ]
Palo-Alto [4 Certification Exam(s) ]
PARCC [1 Certification Exam(s) ]
PayPal [1 Certification Exam(s) ]
Pegasystems [12 Certification Exam(s) ]
PEOPLECERT [4 Certification Exam(s) ]
PMI [15 Certification Exam(s) ]
Polycom [2 Certification Exam(s) ]
PostgreSQL-CE [1 Certification Exam(s) ]
Prince2 [6 Certification Exam(s) ]
PRMIA [1 Certification Exam(s) ]
PsychCorp [1 Certification Exam(s) ]
PTCB [2 Certification Exam(s) ]
QAI [1 Certification Exam(s) ]
QlikView [1 Certification Exam(s) ]
Quality-Assurance [7 Certification Exam(s) ]
RACC [1 Certification Exam(s) ]
Real Estate [1 Certification Exam(s) ]
Real-Estate [1 Certification Exam(s) ]
RedHat [8 Certification Exam(s) ]
RES [5 Certification Exam(s) ]
Riverbed [8 Certification Exam(s) ]
RSA [15 Certification Exam(s) ]
Sair [8 Certification Exam(s) ]
Salesforce [5 Certification Exam(s) ]
SANS [1 Certification Exam(s) ]
SAP [98 Certification Exam(s) ]
SASInstitute [15 Certification Exam(s) ]
SAT [1 Certification Exam(s) ]
SCO [10 Certification Exam(s) ]
SCP [6 Certification Exam(s) ]
SDI [3 Certification Exam(s) ]
See-Beyond [1 Certification Exam(s) ]
Siemens [1 Certification Exam(s) ]
Snia [7 Certification Exam(s) ]
SOA [15 Certification Exam(s) ]
Social-Work-Board [4 Certification Exam(s) ]
SpringSource [1 Certification Exam(s) ]
SUN [63 Certification Exam(s) ]
SUSE [1 Certification Exam(s) ]
Sybase [17 Certification Exam(s) ]
Symantec [135 Certification Exam(s) ]
Teacher-Certification [4 Certification Exam(s) ]
The-Open-Group [8 Certification Exam(s) ]
TIA [3 Certification Exam(s) ]
Tibco [18 Certification Exam(s) ]
Trainers [3 Certification Exam(s) ]
Trend [1 Certification Exam(s) ]
TruSecure [1 Certification Exam(s) ]
USMLE [1 Certification Exam(s) ]
VCE [6 Certification Exam(s) ]
Veeam [2 Certification Exam(s) ]
Veritas [33 Certification Exam(s) ]
Vmware [58 Certification Exam(s) ]
Wonderlic [2 Certification Exam(s) ]
Worldatwork [2 Certification Exam(s) ]
XML-Master [3 Certification Exam(s) ]
Zend [6 Certification Exam(s) ]
Dropmark : http://killexams.dropmark.com/367904/11649451
Wordpress : http://wp.me/p7SJ6L-10B
Issu : https://issuu.com/trutrainers/docs/250-511
Dropmark-Text : http://killexams.dropmark.com/367904/12149444
Blogspot : http://killexamsbraindump.blogspot.com/2017/11/looking-for-250-511-exam-dumps-that.html
RSS Feed : http://feeds.feedburner.com/JustMemorizeThese250-511QuestionsBeforeYouGoForTest
weSRCH : https://www.wesrch.com/business/prpdfBU1HWO000PGKF
Box.net : https://app.box.com/s/5r2u6vfx48ncpeh44ywv1cpc3xntdr9g
publitas.com : https://view.publitas.com/trutrainers-inc/pass4sure-250-511-dumps-and-practice-tests-with-real-questions
zoho.com : https://docs.zoho.com/file/5r1nh86271bcfec424501bd6f46d4184572be
Calameo : http://en.calameo.com/books/004923526e89f6a9daa22